Dataset Information

CLigOpt: controllable ligand design through target-specific optimization.

ABSTRACT:

Motivation

A key challenge in deep generative models for molecular design is to navigate random sampling of the vast molecular space, and produce promising molecules that strike a balance across multiple chemical criteria. Fragment-based drug design (FBDD), using fragments as starting points, is an effective way to constrain chemical space and improve generation of biologically active molecules. Furthermore, optimization approaches are often implemented with generative models to search through chemical space, and identify promising samples which satisfy specific properties. Controllable FBDD has promising potential in efficient target-specific ligand design.

Results

We propose a controllable FBDD model, CLigOpt, which can generate molecules with desired properties from a given fragment pair. CLigOpt is a variational autoencoder-based model which utilizes co-embeddings of node and edge features to fully mine information from molecular graphs, as well as a multi-objective Controllable Generation Module to generate molecules under property controls. CLigOpt achieves consistently strong performance in generating structurally and chemically valid molecules, as evaluated across six metrics. Applicability is illustrated through ligand candidates for hDHFR and it is shown that the proportion of feasible active molecules from the generated set is increased by 10%. Molecular docking and synthesizability prediction tasks are conducted to prioritize generated molecules to derive potential lead compounds.

Availability and implementation

The source code is available via https://github.com/yutongLi1997/CLigOpt-Controllable-Ligand-Design-through-Target-Specific-Optimisation.

SUBMITTER: Li Y

PROVIDER: S-EPMC11373314 | biostudies-literature | 2024 Sep

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

CLigOpt: controllable ligand design through target-specific optimization.

Li Yutong Y Avelar Pedro Henrique da Costa PHDC Chen Xinyue X Zhang Li L Wu Min M Tsoka Sophia S

Bioinformatics (Oxford, England) 20240901 Suppl 2

<h4>Motivation</h4>A key challenge in deep generative models for molecular design is to navigate random sampling of the vast molecular space, and produce promising molecules that strike a balance across multiple chemical criteria. Fragment-based drug design (FBDD), using fragments as starting points, is an effective way to constrain chemical space and improve generation of biologically active molecules. Furthermore, optimization approaches are often implemented with generative models to search t ...[more]

PMID: 39230708

Similar Datasets

Project description:BACKGROUND:RNAs are attractive molecules as the biological parts for synthetic biology. In particular, the ability of conformational changes, which can be encoded in designer RNAs, enables us to create multistable molecular switches that function in biological circuits. Although various algorithms for designing such RNA switches have been proposed, the previous algorithms optimize the RNA sequences against the weighted sum of objective functions, where empirical weights among objective functions are used. In addition, an RNA design algorithm for multiple pseudoknot targets is currently not available. RESULTS:We developed a novel computational tool for automatically designing RNA sequences which fold into multiple target secondary structures. Our algorithm designs RNA sequences based on multi-objective genetic algorithm, by which we can explore the RNA sequences having good objective function values without empirical weight parameters among the objective functions. Our algorithm has great flexibility by virtue of this weight-free nature. We benchmarked our multi-target RNA design algorithm with the datasets of two, three, and four target structures and found that our algorithm shows better or comparable design performances compared with the previous algorithms, RNAdesign and Frnakenstein. In addition to the benchmarks with pseudoknot-free datasets, we benchmarked MODENA with two-target pseudoknot datasets and found that MODENA can design the RNAs which have the target pseudoknotted secondary structures whose free energies are close to the lowest free energy. Moreover, we applied our algorithm to a ribozyme-based ON-switch which takes a ribozyme-inactive secondary structure when the theophylline aptamer structure is assumed. CONCLUSIONS:Currently, MODENA is the only RNA design software which can be applied to multiple pseudoknot targets. Successful design results for the multiple targets and an RNA device indicate usefulness of our multi-objective RNA design algorithm.

Project description:Under-sampling artifacts are a major problem in four-dimensional cone-beam computed tomography (4D-CBCT) and may compromise evaluation of target motion. Several studies have addressed scan parameter selection for minimizing under-sampling artifacts; however, the role of the target characteristics in scan parameter selection has not been investigated. In this work, the authors evaluated 4D-CBCT performance by assessing the accuracy of target motion measurements for various target sizes and motions. The results may serve as patient-specific guidelines for scan parameters selection in 4D-CBCT.The authors acquired 4D-CBCT scans of a moving phantom consisting of six water-filled sphere targets of sizes 10-37 mm, using various scan times ranging from 30 s to 3 min., setting the motion to 3-s and 6-s periods. The authors used automatic image registration to extract the target motion trajectories and evaluated these measurements for various target sizes and motions over various combinations of scan parameters including scan time, detector configuration, number of respiration phases, and reconstruction filters.The most important object parameter to 4D-CBCT performance was the period of motion. Measurements for the 6-s motion were always systematically less accurate than measurements for the 3-s motion for 34 of 36 objects of various sizes and periods of motion. The 6-s motion required a greater scan time than the 3-s motion for equivalent measurement accuracy. The second most influential parameter was the target size. For the 3-s period of motion, objects larger than 13 mm were tracked with sub-millimeter accuracy with a 1-min scan time. For the 6-s period of motion, objects larger than 22-mm were tracked with sub-millimeter accuracy with a 1.5-min scan time. For all sizes and motions, temporal blurring was observed when the number of phases was fewer than 8. Offset detector configuration provided the same performance as centered detector except for small targets (20 mm.) at short scan times (≤1 min). Finally, reconstruction filtering and number of respiratory phases did not affect performance.Scan time should be set according to target size and motion. The authors have provided figures that provide the minimum scan time needed to achieve the particular motion measurement accuracy for a particular size and motion period.

Project description:Alzheimer disease (AD) is now considered as a multifactorial neurodegenerative disorder and rapidly increasing to an alarming situation and causing higher death rate. One target one ligand hypothesis does not provide complete solution of AD due to multifactorial nature of the disease and one target one drug fails to provide better treatment against AD. Moreover, currently available treatments are limited and most of the upcoming treatments under clinical trials are based on modulating single target. So, the current AD drug discovery research is shifting towards a new approach for a better solution that simultaneously modulates more than one targets in the neurodegenerative cascade. This can be achieved by network pharmacology, multi-modal therapies, multifaceted, and/or the more recently proposed term "multi-targeted designed drugs". Drug discovery project is a tedious, costly and long-term project. Moreover, multi-target AD drug discovery added extra challenges such as the good binding affinity of ligands for multiple targets, optimal ADME/T properties, no/less off-target side effect and crossing of the blood-brain barrier. These hurdles may be addressed by insilico methods for an efficient solution in less time and cost as computational methods successfully applied to single target drug discovery project. Here, we are summarizing some of the most prominent and computationally explored single targets against AD and further, we discussed a successful example of dual or multiple inhibitors for same targets. Moreover, we focused on ligand and structure-based computational approach to design MTDL against AD. However, it is not an easy task to balance dual activity in a single molecule but computational approach such as virtual screening docking, QSAR, simulation and free energy is useful in future MTDLs drug discovery alone or in combination with a fragment-based method. However, rational and logical implementations of computational drug designing methods are capable of assisting AD drug discovery and play an important role in optimizing multi-target drug discovery.

Dataset Information

CLigOpt: controllable ligand design through target-specific optimization.

Motivation

Results

Availability and implementation

Publications

CLigOpt: controllable ligand design through target-specific optimization.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets